# IDEXX LABORATORIES INC /DE (IDXX) · Edgar & Edgarette company card

> Idexx Laboratories (IDXX) grew revenue 10.4% in FY2025 to $4.3 billion, operating margin 31.6% against a -4.3% median for in vitro & in vivo diagnostic substances, equity 47.9% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 874716 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/IDXX) · [JSON](https://www.pops4.com/boards/company/IDXX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $4.3B |
| Revenue growth, 1 year | 10.4% |
| Revenue growth per year | 7.6% |
| Operating margin | 31.6% (prior year 29.0%) |
| Net margin | 24.6% |
| Operating cash flow | $1.2B |
| Capital spending | $125M |
| Free cash flow | $1.1B |
| Cash | $180M |
| Long-term debt | $450M |
| Total assets | $3.4B |
| Total equity | $1.6B |
| Equity ÷ assets | 47.9% |
| Return on equity | 66.0% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 10.43 (safe zone)
- Piotroski F: 8 of 9 (strong)
- Beneish M: -2.5 (below the −1.78 line)
- Health Harbor boat: New ship · no warning signs
- Cash Compass: Cash cow later · growing fast, and already turning revenue into cash

## Edgarette's reading

Exposure: revenue $4.3B (FY2025), total debt $450.0M. Experience: revenue up 10.4% on the year, up 7.6% a year over 4 years; operating margin 31.6%, up from 29.0%. Soundness: equity 47.9% of assets, return on equity 66.0%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $4.2B and $5.0B next year (method v4.1: its own 4-year record of growth weighed at 50% against $1B–10B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $4.0B to $5.3B. A statistical range, not company guidance. Against peers (161 filers, $50M+ revenue, its industry group): operating margin 31.6% against a -4.3% median; growth 10.4% against 12.6%.

Range logged 2026-09-26, receipt b813447088e888e9, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 3, latest 2026-03-26 ([filing](https://www.sec.gov/Archives/edgar/data/874716/000110465926034906/0001104659-26-034906-index.htm))

## Recent filings

- 10-Q · filed 2026-11-02 · [filing](https://www.sec.gov/Archives/edgar/data/874716/000087471626000135/0000874716-26-000135-index.htm)
- 8-K · filed 2026-11-02 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/874716/000110465926120892/0001104659-26-120892-index.htm)
- 10-Q · filed 2026-08-04 · [filing](https://www.sec.gov/Archives/edgar/data/874716/000087471626000123/0000874716-26-000123-index.htm)
- 8-K · filed 2026-08-04 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/874716/000110465926090033/0001104659-26-090033-index.htm)
- 8-K · filed 2026-05-15 · 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/874716/000087471626000110/0000874716-26-000110-index.htm)
- 10-Q · filed 2026-05-05 · [filing](https://www.sec.gov/Archives/edgar/data/874716/000087471626000076/0000874716-26-000076-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000874716.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=874716

## Cite

POPS4, Edgar & Edgarette: IDEXX LABORATORIES INC /DE (IDXX) company card, from the company's own SEC filings, accessed 2026-11-10, https://www.pops4.com/boards/company/IDXX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.